摘要:
The present invention provides particular anti-inflammatory factors, compositions containing them, methods of making, identifying, and/or characterizing them, and methods of using them. In some embodiments, provided factors are expressed by human bone marrow stromal cells (MSC). In some embodiments, provided factors are characterized by an ability, when contacted with mammalian leukocytes in culture, to alter production of at least one inflammatory or anti-inflammatory agent by the mammalian leukocytes. In some embodiments, provided factors include GALNT1 polypeptides, LGALS3BP polypeptides, MFAP5 polypeptides, PENK polypeptides and/or HAPLN1 polypeptides. In some embodiments, provided factors are useful in the inhibition of inflammatory agents, in the promotion of anti-inflammatory agents, and/or for the treatment of subjects suffering from or susceptible to a disease, disorder or condition characterized by inflammation.
摘要:
The invention provides compositions and methods for modulating disease using hematopoietic stromal progenitor cells derived from hematopoietic tissues. The invention further provides methods for isolating, storing and culturing hematopoietic stromal progenitor cells.
摘要:
The invention provides compositions and methods for modulating immune responses using mesenchymal stem cells. The invention further provides methods for inducing tolerance to self antigens using mesenchymal stem cells.
摘要:
Described are compositions and methods for treating liver disease, e.g., acute liver disease, using bone marrow-derived stem cells and bone marrow-derived stem cell conditioned media.
摘要:
Described are compositions and methods for treating liver disease, e.g., acute liver disease, using bone marrow-derived stem cells and bone marrow-derived stem cell conditioned media.
摘要:
Described are compositions and methods for treating liver disease, e.g., acute liver disease, using bone marrow-derived stem cells and bone marrow-derived stem cell conditioned media.